Dare Bioscience Inc (NASDAQ:DARE) Director Roger Hawley acquired 140,000 shares of Dare Bioscience stock in a transaction on Monday, June 11th. The stock was purchased at an average price of $1.45 per share, with a total value of $203,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Dare Bioscience opened at $1.31 on Thursday, Marketbeat.com reports. Dare Bioscience Inc has a 12 month low of $0.74 and a 12 month high of $12.40. The company has a market cap of $16.91 million, a PE ratio of -1.06 and a beta of 2.74.
Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Monday, April 2nd. The biotechnology company reported ($0.49) EPS for the quarter. research analysts forecast that Dare Bioscience Inc will post -1.26 EPS for the current fiscal year.
A number of brokerages have weighed in on DARE. Roth Capital began coverage on Dare Bioscience in a research note on Wednesday, May 16th. They issued a “buy” rating and a $6.00 price objective for the company. ValuEngine upgraded Dare Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
About Dare Bioscience
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.